Read More

Celyad Oncology Reports Q3 Financial Review As Of September 30, The Company Had Cash And Cash Equivalents Of $13.1M; Clinical Updates Expected By End Of Year For The Phase 1 Dose-escalation IMMUNICY-1 Trial For Lead ShRNA-based Allogeneic Car T Candida…

Company continues to transition business focus to monetizing unique cell therapy intellectual property and prioritizing R&D discovery Clinical updates expected by end of year for the Phase 1 dose-escalation

CYAD

Read More

FDA Committee Voted 8-5 That Known Potential Benefits Do Not Outweigh The Known And Potential Risks Of Sabizabulin. Input Of The Advisory Committee As Part Of Their Review Of The EUA And Render A Decision On The Emergency Use Authorization

Veru Inc. (NASDAQ:VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, announces the results of today's meeting of the U.S.

VERU